중추신경계 바이오마커 시장 : 세계 예측(2026-2032년)

The Central Nervous System Biomarkers Market is projected to grow by USD 10.66 billion at a CAGR of 7.63% by 2032.

Central Nervous System Biomarkers Executive Summary

Central nervous system biomarkers are measurable biological indicators used to support the detection, diagnosis, prognosis, monitoring, and therapeutic evaluation of neurological and psychiatric disorders. These biomarkers include molecular signals in cerebrospinal fluid and blood, neuroimaging indicators, electrophysiological measures, digital behavioral markers, genetic and proteomic signatures, and emerging multi-omics profiles. Their clinical relevance is expanding as healthcare systems respond to rising burdens from Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, stroke, traumatic brain injury, major depressive disorder, and other CNS conditions documented by global public health and neurology research programs.

The field is moving from symptom-led assessment toward biomarker-supported precision neurology and precision psychiatry. Regulatory agencies have increasingly emphasized biomarker qualification, real-world evidence, and patient enrichment strategies in CNS drug development, while clinical researchers are prioritizing minimally invasive blood-based biomarkers, standardized imaging protocols, and longitudinal monitoring tools. In parallel, advances in assay sensitivity, neurofilament light chain testing, amyloid and tau detection, synaptic markers, inflammatory biomarkers, and digital cognition tools are improving the ability to identify disease activity earlier and measure progression more objectively.

For industry leaders, the opportunity lies not in broad claims but in validated, clinically interpretable, and workflow-ready biomarker solutions. Successful adoption depends on analytical validity, clinical utility, reimbursement readiness, data interoperability, ethical governance, representative validation cohorts, and demonstrable value in improving patient outcomes and clinical trial efficiency.

Transformative Shifts in the CNS Biomarkers Landscape

The CNS biomarkers landscape is undergoing transformative change as research moves beyond single-analyte models toward integrated biomarker panels that combine fluid, imaging, genetic, electrophysiological, and digital signals. Blood-based biomarkers are drawing strong clinical interest because they offer a less invasive alternative to cerebrospinal fluid sampling and can support scalable screening, triage, and longitudinal monitoring. In Alzheimer's disease research, plasma phosphorylated tau, amyloid-beta ratios, glial fibrillary acidic protein, and neurofilament light chain have shown strong associations with neurodegeneration, amyloid pathology, tau pathology, and disease progression in peer-reviewed studies, accelerating their evaluation for clinical use.

Clinical trials are also shifting. Biomarkers are increasingly used for participant selection, target engagement, pharmacodynamic assessment, safety monitoring, and stratification of heterogeneous CNS populations. This is especially important because CNS disorders often present with overlapping symptoms and variable disease trajectories. Biomarker-guided trial designs can reduce diagnostic uncertainty, support earlier intervention, and improve the interpretability of therapeutic response.

Healthcare delivery is evolving as well. Neurology practices, memory clinics, academic hospitals, and specialized laboratories are adopting more standardized protocols for sample handling, imaging interpretation, and cognitive assessment. At the same time, digital biomarkers collected through wearables, smartphones, speech analysis, gait assessment, sleep monitoring, and passive activity tracking are creating new opportunities for remote measurement of motor, cognitive, and behavioral changes. The strongest shift is toward evidence-linked biomarker ecosystems that can connect laboratory data, imaging data, clinical records, and real-world patient monitoring into actionable decision support.

Cumulative Impact of Artificial Intelligence on CNS Biomarkers

Artificial intelligence is reshaping CNS biomarker discovery, validation, and deployment by enabling pattern recognition across complex biological and clinical datasets. Machine learning models are being applied to neuroimaging, genomics, proteomics, metabolomics, electronic health records, speech patterns, movement data, and digital cognitive assessments to identify disease signatures that may not be visible through conventional statistical methods. In radiology and neuroscience research, AI-assisted image analysis supports automated segmentation, lesion quantification, brain atrophy assessment, connectivity analysis, and detection of subtle structural or functional changes.

The cumulative impact of AI is particularly important in disorders with high biological heterogeneity, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, traumatic brain injury, and major psychiatric conditions. AI can support multimodal biomarker panels by integrating fluid markers with imaging, clinical scales, medication history, genetics, environmental exposure data, and longitudinal outcomes. This creates potential for more precise phenotyping, earlier risk identification, and better prediction of disease progression.

However, AI adoption in CNS biomarkers requires disciplined governance. Models must be trained on diverse and representative datasets, externally validated, monitored for bias, and aligned with clinical interpretability standards. Data privacy, cybersecurity, explainability, and regulatory traceability are essential, particularly when AI outputs influence diagnosis, trial eligibility, or treatment monitoring. The most sustainable AI strategies will combine high-quality annotated data, transparent model development, clinician oversight, and evidence of measurable improvement in clinical or research decision-making.

Key Regional Insights Across CNS Biomarkers

Asia-Pacific is becoming an increasingly important region for CNS biomarker development due to aging populations, expanding neuroscience research infrastructure, and rising diagnosis of neurodegenerative disorders in China, Japan, South Korea, India, and Australia. Japan's long-standing focus on dementia care and neuroimaging research, South Korea's digital health capabilities, China's large-scale clinical research networks, India's growing diagnostics capacity, and Australia's strength in cohort studies and neurological research collectively support regional momentum. The region also faces challenges related to uneven access to advanced diagnostics, differences in laboratory standardization, variability in reimbursement pathways, and the need for population-specific validation of blood-based, imaging, and digital CNS biomarkers.

Europe is characterized by strong regulatory coordination, cross-border research networks, and established expertise in neurology, psychiatry, imaging, and biomarker standardization. The region's emphasis on data protection, ethical research, in vitro diagnostic regulation, and clinical evidence generation shapes biomarker adoption. Germany, France, Italy, Spain, the United Kingdom, and Nordic research ecosystems support advances in dementia, multiple sclerosis, Parkinson's disease, epilepsy, and psychiatric biomarker studies, while harmonized research frameworks strengthen multicenter validation and real-world evidence collection.

North America remains highly influential in CNS biomarker research because of its concentration of academic medical centers, specialized neurology networks, biobanks, regulatory science initiatives, and clinical trial activity. The United States has been central to Alzheimer's disease biomarker research, neurofilament light chain evaluation, advanced imaging protocols, and digital biomarker development, while Canada contributes through population health research, neuroscience collaboration, and public health-linked neurological datasets. Adoption is supported by advanced laboratory infrastructure, although payer evidence requirements, clinical implementation standards, and equitable access remain critical factors.

Latin America is building capacity in CNS biomarker research as neurological disease burden rises and regional centers increase participation in clinical studies. Brazil and Mexico are key contributors due to their academic hospitals, growing genomics and diagnostics capabilities, and large patient populations. However, disparities in specialist access, limited availability of advanced neuroimaging in some areas, fragmented reimbursement structures, and underrepresentation in global biomarker cohorts can slow routine clinical integration.

Africa presents an important long-term opportunity for CNS biomarker research due to genetic diversity, infectious and noncommunicable neurological disease intersections, and growing academic partnerships. Limited laboratory infrastructure, unequal access to neurologists, and underrepresentation in global biomarker datasets highlight the need for inclusive research models, sustainable capacity building, and locally relevant validation. The Middle East is expanding its neuroscience and precision medicine capabilities through investments in tertiary care, genomics, and specialized diagnostic infrastructure, particularly in Gulf countries. Growth is supported by healthcare modernization and interest in advanced neurological care, but local validation, workforce development, and integrated care pathways remain priorities.

Key Economic and Strategic Group Insights

NATO countries overlap substantially with high-capacity research systems in North America and Europe, where military and civilian interest in traumatic brain injury, neurocognitive health, mental resilience, sleep disruption, and rehabilitation has supported research into objective neurological, behavioral, and digital biomarkers. This group is especially relevant for CNS biomarker applications tied to concussion assessment, post-traumatic stress symptoms, cognitive performance monitoring, and long-term neurological outcomes, while strict requirements for data security, interoperability, and ethical use shape implementation.

G7 countries remain central to CNS biomarker innovation due to advanced research institutions, regulatory expertise, laboratory infrastructure, and clinical trial networks. The group is influential in setting standards for biomarker validation, neuroimaging protocols, data quality, AI governance, and therapeutic monitoring in neurodegenerative and neuroinflammatory diseases. These countries also play a major role in evidence generation for Alzheimer's disease biomarkers, multiple sclerosis monitoring, Parkinson's disease research, and digital CNS measurement tools.

BRICS economies represent a major axis for future CNS biomarker development because they combine large patient populations, growing research capacity, and increasing investment in biotechnology and healthcare modernization. China, India, Brazil, Russia, and South Africa offer opportunities for diverse cohort development and real-world neurological data generation, which are essential for improving biomarker generalizability. However, infrastructure variability, regulatory differences, and uneven access to specialized neurology services require locally adapted implementation strategies.

The European Union benefits from coordinated research funding, multicountry clinical studies, strict data governance, and established frameworks for in vitro diagnostics, medical devices, and health technology assessment. These conditions support rigorous validation of CNS biomarkers and encourage harmonization of laboratory methods, imaging protocols, and real-world evidence collection. The EU's focus on ethical AI, data interoperability, and patient-centered care is particularly relevant for multimodal and digital CNS biomarkers.

ASEAN countries are advancing CNS biomarker relevance through expanding hospital networks, growing digital health adoption, and increasing attention to dementia, stroke, epilepsy, neurodevelopmental conditions, and mental health. Singapore plays a strong role in biomedical research and clinical translation, while Indonesia, Thailand, Malaysia, the Philippines, and Vietnam represent significant patient populations where scalable blood-based and digital biomarkers may help address specialist access gaps. Regional success depends on harmonized data standards, affordable diagnostics, and multicenter validation across diverse populations.

The GCC is strengthening CNS biomarker capabilities through investment in precision medicine, tertiary hospitals, genomics programs, and digital healthcare infrastructure. Countries in the group are well positioned to adopt advanced neurodiagnostics in specialized centers, particularly for dementia, multiple sclerosis, epilepsy, stroke, and rare neurological disorders. Local population studies, clinical workforce training, reimbursement clarity, and integrated referral pathways will be essential to ensure that biomarker tools move beyond premium care settings into broader clinical pathways.

Key Country Insights for CNS Biomarker Adoption

China is rapidly expanding CNS biomarker research through large hospital networks, national neuroscience initiatives, genomics capacity, and AI-enabled healthcare research. The United States leads in CNS biomarker translation through extensive clinical trial networks, advanced laboratory platforms, neuroimaging expertise, biobanking, and regulatory engagement around biomarker qualification and companion diagnostic pathways. Japan has deep expertise in aging-related neuroscience, dementia diagnostics, neuroimaging, and Parkinson's disease research, supported by one of the world's oldest populations. India has strong potential due to its large and diverse population, growing diagnostics sector, and increasing focus on neurological and mental health burden, though access differences between urban tertiary centers and rural regions remain important.

Germany is prominent in neurology, laboratory medicine, multiple sclerosis research, and hospital-based diagnostic infrastructure, supporting strong adoption conditions for validated CNS biomarkers. The United Kingdom has strong capabilities in dementia research, biobanking, neuroimaging, digital health studies, and population-linked health datasets. Australia contributes through longitudinal cohort research, brain health programs, clinical trial participation, and digital health readiness. France contributes through neuroscience institutes, imaging research, neurodegenerative disease programs, and coordinated clinical research networks. South Korea combines advanced healthcare infrastructure, biomedical research capacity, and digital technology strengths, supporting innovation in imaging, fluid biomarkers, and remote neurological monitoring.

Italy and Spain have established clinical neurology networks and active research in Alzheimer's disease, Parkinson's disease, epilepsy, stroke, and multiple sclerosis, with adoption shaped by regional care pathways and reimbursement processes. Canada contributes through neuroscience research, population-based health data, collaborative clinical programs, and public health-linked neurological datasets. Russia has scientific capacity in neuroscience and clinical neurology, although international collaboration dynamics and healthcare system structure influence the pace of global integration. Brazil is a leading Latin American contributor, supported by major academic centers, diverse populations, and expanding participation in neurology research. Mexico is strengthening diagnostic and research capabilities amid rising attention to dementia, stroke, epilepsy, and neurological care access.

Actionable Recommendations for CNS Biomarker Leaders

Industry leaders should prioritize clinically validated CNS biomarker solutions that address clear decision points, such as early detection, differential diagnosis, prognosis, treatment selection, monitoring of disease activity, safety assessment, and clinical trial enrichment. Development strategies should begin with robust analytical validation, including assay precision, reproducibility, pre-analytical controls, reference materials, and inter-laboratory comparability. Clinical validation should reflect real-world disease heterogeneity, comorbidities, age differences, sex differences, ethnicity, medication effects, disease stage, and care setting variation.

Organizations should build multimodal biomarker strategies that integrate blood-based testing, cerebrospinal fluid analysis, neuroimaging, cognitive measures, digital biomarkers, electrophysiology, and patient-reported outcomes where clinically justified. Data infrastructure should support interoperability with electronic health records, imaging archives, laboratory information systems, registries, and research databases. AI-enabled tools should be explainable, externally validated, continuously monitored, and governed by transparent model performance standards.

Commercial and clinical adoption require evidence beyond technical performance. Leaders should generate health economic evidence, workflow impact data, clinical utility studies, and physician education programs. Partnerships with academic centers, hospitals, patient registries, public health initiatives, and community-based research networks can strengthen dataset diversity and improve generalizability. Organizations should also prepare for evolving regulatory expectations around diagnostic claims, software as a medical device, data privacy, and post-market surveillance. Above all, equitable access should be embedded into product design, pricing, validation cohorts, and implementation planning.

Research Methodology for CNS Biomarker Analysis

This executive summary is developed through a structured secondary research approach focused on verified, data-backed sources relevant to central nervous system biomarkers. The methodology includes review and synthesis of peer-reviewed scientific literature, clinical guidelines, regulatory publications, public health data, biomarker qualification frameworks, disease-focused research consortium outputs, and publicly available information from recognized healthcare and neuroscience institutions. Priority is given to evidence from multicenter studies, systematic reviews, longitudinal cohorts, regulatory science documents, and clinically validated biomarker research.

The analysis evaluates CNS biomarkers across major modalities, including fluid biomarkers, neuroimaging markers, electrophysiological measures, digital biomarkers, genetic indicators, proteomic and metabolomic signatures, and AI-enabled multimodal models. Regional, group, and country insights are assessed based on healthcare infrastructure, research capacity, diagnostic access, clinical trial activity, regulatory maturity, aging demographics, digital health adoption, data governance, and neurological disease priorities. The methodology avoids speculative market sizing, revenue estimates, market share claims, and forecasting, focusing instead on evidence-based trends, adoption conditions, and strategic implications.

Quality control includes cross-checking claims across multiple credible sources, excluding unsupported promotional assertions, and distinguishing established clinical utility from emerging research potential. The resulting summary is designed to support executive decision-making, relevance, and strategic planning without relying on unverified projections.

Conclusion: Evidence-Led Growth in CNS Biomarkers

Central nervous system biomarkers are becoming foundational to the next phase of neurology, psychiatry, and CNS drug development. The strongest progress is occurring where validated biological measures are connected to clear clinical decisions, standardized workflows, and longitudinal patient monitoring. Blood-based biomarkers, advanced neuroimaging, electrophysiological measures, digital measures, and AI-enabled multimodal analysis are expanding what can be measured, but clinical value depends on reproducibility, interpretability, equitable validation, and integration into care pathways.

Regional dynamics show that North America and Europe remain influential in validation standards, regulatory science, and clinical trial infrastructure, while Asia-Pacific is rapidly strengthening research scale and translational capacity. Latin America, the Middle East, and Africa present important opportunities for inclusive biomarker development, particularly as global research recognizes the need for more diverse datasets and locally relevant implementation models.

The future of CNS biomarkers will be defined by evidence quality rather than technology novelty. Stakeholders that invest in rigorous validation, interoperable data systems, ethical AI, diverse cohorts, and real-world clinical utility will be best positioned to support earlier diagnosis, more precise treatment strategies, stronger clinical trial design, and more efficient CNS research programs.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Central Nervous System Biomarkers Market, by Type

• 7.1. Introduction
• 7.2. Molecular Biomarkers
  • 7.2.1. DNA Based Biomarkers
  • 7.2.2. RNA Based Biomarkers
  • 7.2.3. Protein Based Biomarkers
• 7.3. Imaging Biomarkers
• 7.4. Genetic Biomarkers
• 7.5. Digital Biomarkers
• 7.6. Metabolic Biomarkers

8. Central Nervous System Biomarkers Market, by Disease Indication

• 8.1. Introduction
• 8.2. Neurodegenerative Diseases
• 8.3. Neurodevelopmental Disorders
• 8.4. Psychotic Disorders

9. Central Nervous System Biomarkers Market, by Technology

• 9.1. Introduction
• 9.2. Immunoassay
  • 9.2.1. ELISA Based Biomarkers
  • 9.2.2. Multiplex Immunoassays
• 9.3. Mass Spectrometry
  • 9.3.1. Proteomics Based Analysis
  • 9.3.2. Metabolomics Profiling
• 9.4. Next-Generation Sequencing
  • 9.4.1. Whole Genome Sequencing
  • 9.4.2. RNA Sequencing

10. Central Nervous System Biomarkers Market, by Application

• 10.1. Introduction
• 10.2. Diagnosis & Therapeutics
• 10.3. Drug Discovery & Development
• 10.4. Personalized Medicine
• 10.5. Prognosis
• 10.6. Research & Development

11. Central Nervous System Biomarkers Market, by End-User

• 11.1. Introduction
• 11.2. Academic Research Institutes
• 11.3. Healthcare Providers
• 11.4. Pharmaceutical & Biotechnology Companies
• 11.5. Hospitals & Clinics

12. Central Nervous System Biomarkers Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Central Nervous System Biomarkers Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Central Nervous System Biomarkers Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Acumen Pharmaceuticals Inc.
• 16.3. Agilent Technologies Inc.
• 16.4. Alector Inc.
• 16.5. Bio-Rad Laboratories Inc.
• 16.6. Biogen Inc.
• 16.7. C2N Diagnostics
• 16.8. Charles River Laboratories International Inc.
• 16.9. Eli Lilly and Company
• 16.10. Eurofins Scientific
• 16.11. F. Hoffmann-La Roche Ltd
• 16.12. Fujirebio
• 16.13. GE HealthCare Technologies Inc.
• 16.14. IQVIA Holdings Inc.
• 16.15. Johnson & Johnson Services Inc.
• 16.16. Laboratory Corporation of America Holdings
• 16.17. Merck KGaA
• 16.18. Myriad Genetics Inc.
• 16.19. Novartis AG
• 16.20. PerkinElmer Inc.
• 16.21. QIAGEN N.V.
• 16.22. Quanterix Corp.
• 16.23. Revvity Inc.
• 16.24. Siemens Healthineers AG
• 16.25. Thermo Fisher Scientific Inc.